AI Insight
This meta-analysis of randomized controlled trials compared two pathways for evaluating patients with suspected myocardial infarction: cardiac troponin testing at 0 and 1 hour versus 0 and 3 hours. Both pathways showed low short-term adverse event rates, but earlier retesting at 1 hour did not reduce emergency department length of stay or clearly increase direct discharge rates. Substantial variation between studies suggests that effectiveness of the 0/1 hour pathway may differ across healthcare systems.
Why it matters
These findings indicate that hospitals should not assume that adopting faster troponin testing protocols will automatically improve patient flow or outcomes. Implementation decisions require consideration of local diagnostic capabilities and organizational factors rather than relying solely on the potential time savings of earlier testing.
Understand the Science
Across the available randomised trials, short-term adverse event rates were low with both pathways, but the pooled safety estimate remained imprecise. On average, earlier cardiac troponin retesting did not reduce emergency department length of stay or clearly increase direct discharge, and substantial between-study heterogeneity indicates that treatment effects might not translate uniformly across health-care systems. For hospitals considering transitioning from a 0/3 h to a 0/1 h pathway, implementation decisions should take broader diagnostic and organisational considerations into account.